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Letters to the Editor 
Pharmacokinetic Variability Caused by 
Gender: Do Women Have Higher 
lndinavir Exposure Than Men? 
To the Editor: The pharmacokinetics of HIV-protease inhibi-
tors a re characterized by high interpatient variability. Thi s vari-
ability can be explai ned by many factors, incl uding drug-drug 
interactions, impaired absorpti on caused by e ither presence or 
absence of food, and patient- re lated factors. Gender may be one 
of these factors, as it is well known that large diffe rences can 
ex ist in the way men and women metaboli ze drugs ( 1,2). So fa r, 
little attention has been paid to the possibility of gender being 
a re levant de termin ant of in terpat ie nt vari ab ility of HIV-
protease inhibitor pharmacokinetics. For ex ampl e, the product 
monograph of indin av ir (Crixivan; Merck & Co., Rahway, NJ, 
U .S.A.) mentions onl y that no influence of gender has been 
noted on indinav ir pharmacokine tics (3), desp ite data from pre-
c lini ca l resea rc h indicating that indin av ir di splays sex -
dependent pharmacokinetics (4). We have rev iewed indinavir 
plasma concentrations in HIV-infected women and compared 
them with indinav ir concentrat ions in a control group of 
men. 
The Department of C lini ca l Pharmacy at the U ni versity 
Medical Centre Nijmegen is a national referra l center for thera-
peutic drug monito1ing of indinavir in The Netherlands. From 
our database we selected a ll female patients who were us ing 
indin av ir. Other inform at ion collected in cluded age, body 
weight, dose reg imen, indication for drug level monitoring, and 
indinavir pl asma concentration. Individual plasma concentra-
ti ons of patients us ing 800 mg of indinav ir every 8 h were 
compared with the time-adjusted plasma concentrati on values 
in a population of 14 HIV-infected patient ( 12 male, 2 fema le) 
from whom an 8- hour pharmacokinetic curve was recorded 
afte r observed intake. The ratio of the indi vidual va lue versus 
the population va lue is ca lled the inclinav ir concentrati on ratio 
(CR). The pharmacokinetic parameters of the popul ati on curve 
(AUC, Cmax, Cm;,,) are comparable w ith literature data of 800 
mg of inclinavir ( 19.1 mg/L per hour, 8.7 mg/L, and 0. 13 mg/L, 
respective ly (3)) . A contro l group of 94 men was chosen by 
random ly selecting inclinav ir plas ma samples that were re-
ceived at the same day of the sa mples from the fema le group. 
Differences between women and men were tested fo r s ignifi -
cance by Mann-Whitney U test o r the two-sample proportion 
test. 
A tota l of 380 samples fro m 220 fema le patients was avail -
able fo r analysis. Out of thi s group, 227 samples came from 
patients us ing 800 mg of inclinavir every 8 hours. The median 
CR of inclinavir in these samples was 1.1 8 (inte rquartile range: 
0 .65- 1.89), with 58.8% of the sampl es having an indinavir 
CR > 1.00. In the control group of 94 men, 6 1 samples came 
from patients using indinav ir 800 mg every 8 hours. The me-
dian CR of inclinav ir in these samples was 0.96 (inte rquartil e 
range: 0.60- 1.70) with 47.4% of the samples having an incli-
nav ir CR > l.00. The difference in the indinavir CRs between 
men and women is not significant (p = . l 9), sugges ting no 
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diffe rence in ind inavir pharmacokinet ics between men and 
women. 
However, some additional comments can be made. First, 
" intoxication" was noted as an indication for drug level moni-
toring in 17.4% of the women versus 6 .6% of the men 
(p = .03). Second, a close reduction of inclinavir to 600 or 400 
mg every 8 hours after a di agnosis of indin avir-relatcd s ide 
effects was app li ed in 9.7% of the fema le patients versus 1. 1 % 
of the male patients (p < .01 ). F inall y, the proportion of patients 
with an inclinavir CR >2.0, which has been assoc iated with an 
increased ri sk of urolog ic compl ain ts (5), was hi gher in women 
than in men (2 1.3% vs. 13. 1 %, p = .15). 
These data ind icate that women , as a group, have roughl y 
simil ar pharmacokinetic parameters of indinav ir compared with 
men , whi ch is in agreement w ith the product labeling (3), but 
that a subgroup of I 0% to 20% of the wo men may have sub-
stanti a lly e levated indinavi r plasma concentrations. Ge nder-
re lated d iffere nces in pharmacokine tics can be attributed to 
metabo lic variations in cytochrome P450 enzymes, protein 
bind ing, and body weight or compositi on ( I ). Even though the 
women in our data set had a lower medi an body weight than the 
men (63 vs. 75 kg) , no re lationship between low body weight 
and increased indinavi r exposure was fo und. 
Recently , sim ilar relationships be tween gender and pharma-
cokinetics were reported for verapam il , which, like indi navir, is 
a cytochrome P450 and P-glycoprote in substrate (6). Elevated 
drug concentrations resu lt in a hi gher risk fo r side effects . 
Several recent cohort studies have confirmed thi s higher inc i-
dence of side effects in women versus men (7,8). Our data 
sugges t that women who experi ence indinavir-re lated toxicity 
may bene fit from dose reduction, under the guidance of thera-
peutic drug monitoring . 
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Multidrug-Resistant HIV-1 RNA and 
Proviral DNA Variants Harboring New 
Dipeptide Insertions in the Reverse 
Transcriptase pol Gene 
To 1/ie E:,di1or: Selection of drug-resistant HIV- I mutants is a 
major cause of antiretrov iral treatment failure . Res istance to 
HTV reverse transcriptase (RT) inhibitors usually resu lts from 
base-pair (bp) substitutions leading to amino-acid replacements 
in the RT po! gene. The substitution mutation QI S lM or insert-
deletion mutations conferring multidrug resistance (MDR) may 
occur in a minority of cases ( l ) . MOR-related inserti ons gen-
erall y consist of two amino-acids fo ll ow ing the po/ 69 RT 
codon (serine-g lyc inc [S-G], scrinc-alaninc [S-A] and scrine-
serine [S-S]), and are associated with high phenotypic resis-
tance to various nucleoside RT inihibitor (NRTI) analogs ( 1-3). 
M anagement of patients harboring MOR variants remains chal-
leng ing ( I ). 
During year I 999, we have prospectively evaluated geno-
typic resistance mutations of plasma HIV- I RNA variants in 
13 1 NRTl -experienced patients failing antiretroviral therapy, 
by usi ng the consensus procedure proposed by the French Na-
tional Agency for AIDS Research (ANRS), as prev iou ly de-
scribed (4). Three of these plasma viruses (2.3%) exhibited a 
two amino-acid insertion fo llowing the codon 69 (glutam ine-
glyci ne [E-S] , va line-alanine [V-AJ and valine-serine lY-SI) 
plu s aminoacid substitution at codon 70 (K70R), in association 
with T2 I SY (patient I ) or T2l SF (patient 3), M I 84V (patient 2) 
or M 1841 (patient 3) substitutions (Tab le 1). The three patients 
had a long-term hi story (med ian, 33 months) of antiretroviral 
TABLE I. Aminoacid sequences in reverse transcriptase HIV-I po! gene and phenorypic resistance to reverse tra11scriptase inhibitors of plasma 
HIV-I RNA and blood mononuclear cells HIV-I proviral DNA , in 3 111ulridrug experienced patients harboring circulating HI V-I variants with 
dipeptide insertions in po! gene 
Pla1.;111a Aminoacid sequences 
HIV- I Antiviral 
load therapy" (log 10 CD4+ T 6 6 62 6 6 6 6 6 6 6 7 7 Other 
copil!~ cell 0 I 3 4 5 6 7 8 9 0 mut ations 
Pati\!nl pc, mL) (per µL) RTI PI v<' F A K K K D s T K w in RT gene 
5.6 127 ABC NFV HIV RNA V F y e K K K D s s E s R w A98G, 
NVP KIOIQ,Yi 81C, 
G i 90A, T2 15Y 
Prov iral V F V K K K D s s E s R w A98G, 
DNA KIOIQ, Yl81C, 
Gl90A, T215Y 
2 4 .2 23 1 d4T HI V R A V F V K K K D s s V A R w M41L, M 184V 
ddl 
Proviral V F V K K K D s V A R w M41L, M184V 
DNA 
3 3.9 456 3TC NFV HI V RNA V F V K K K D s s V s R w M1 84 1, T2 15F 
d4T 
Proviral V F V K K K D s T R w 
D A 
RVA index for drugb.c 
Patient Sample AZT 3TC d4T ddl ABC EFV NVP 
I HIV RNA/proviral DNA >30 1 >6 19 >550 >400 20 >947 
2 HIV RNA/prov iral DNA >3688 >346 14.8 9 I 
3 2 lines HIV R A and proviral D A >5 6 >6 19 322 < I 
ND ND ND ND 
"Antirctroviral therapy taken at time of res istance genotype determination. "Phenotypic results are expressed as RVA index determined fo r each 
drug te,tcd: RV A index< 4 indicates phenotypic sensi ti vity; RV A index between 4 and I 0 indicates low level of resistance; RV A index > I 0 indicates 
high level of re, istance. csince the same genotypic pattern was observed in the HIV- I RNA and D A RT po! gene, the RVA indexes for plasma HIV- I 
RNA and PBMC HIV- I DNA were considered similar. din italics are shown the aminoacids of consensus HIV- I RT sequence of the HXB2 reference 
HI Y- 1 strain. ' In bold are shown codons harboring mutated aminoacids by reference to the HXB2 H- 1 strain . (-) represents aminoacid insertions. 
ND. not determined; RT, reverse transcriptase; RTI, reverse transcriptase inhibitor; PI, protease inhibitor; RVA, recombinant virus reverse transcrip-
tase inhibitor sensi ti vity assay; PBMC, peripheral blood mononuclear cell s; ABC, abacavi r; EFV, efavirenz; NVP, nevirapine; NFV, nelfinavi r; d4T, 
stavud ine; dell. diclanosine; 3TC, lamivudine. 
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